<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101889</url>
  </required_header>
  <id_info>
    <org_study_id>REC.56-036-13-1-1</org_study_id>
    <nct_id>NCT05101889</nct_id>
  </id_info>
  <brief_title>Benefits of Immunonutrition in Patients With Head and Neck Cancer Receiving Chemoradiation</brief_title>
  <official_title>Benefits of Immunonutrition in Patients With Head and Neck Cancer Receiving Chemoradiation: A Phase II Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the benefits of immunonutrition regarding the prevention of severe&#xD;
      mucositis. Patients with head and neck cancer (HNC) undergoing definitive concurrent&#xD;
      chemoradiation including 3-week cycles of cisplatin were enrolled in this double-blind phase&#xD;
      II study. Patients were randomly assigned to receive an immunonutrition containing&#xD;
      omega-3-fatty acids, arginine, dietary nucleotides, and soluble fiber or an isocaloric&#xD;
      isonitrogenous control. All patients received the assigned product 5 days before each&#xD;
      chemotherapy session. The proportion of patients with severe mucositis was compared between&#xD;
      the immunonutrition and control groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2013</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase II randomized, double-blind study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria</measure>
    <time_frame>6 weeks after initiation of concurrent chemoradiation (CCRT)</time_frame>
    <description>Proportion of severe oral mucositis between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other treatment-related toxicities graded according to the NCI CTCAE version 4.03 criteria</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>Proportion of patients with other treatment-related toxicities between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight in kilograms</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean changes of body weight between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum albumin in grams per deciliter (g/dL)</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean serum albumin between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin in grams per deciliter (g/dL)</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean hemoglobin between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) in milligrams per liter (mg/L)</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean CRP between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil-to-lymphocyte ratio (NLR)</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean NLR between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet-to-lymphocyte ratio (PLR)</measure>
    <time_frame>6 weeks after initiation of CCRT and 1 month after CCRT completion</time_frame>
    <description>mean PLR between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>actual dose of radiation in centigrays (cGy)</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>mean actual dose of radiation between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative dose of cisplatin in milligrams per square meter (mg/m2)</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>mean cumulative dose of cisplatin between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>at 3 years</time_frame>
    <description>compare PFS between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>at 3 years</time_frame>
    <description>compare OS between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Immunonutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral immunomodulating formula (Oral Impact®, Nestle) One sachet of Oral Impact® consisted of 74 g of powder providing 303 kilocalories.&#xD;
Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An isocaloric isonitrogenous standard enteral nutrition formula. Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Impact®</intervention_name>
    <description>3 ready-to-drink bottles/day</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Immunonutrition</arm_group_label>
    <other_name>Blendera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of 18-65 years&#xD;
&#xD;
          -  histological confirmation of stage II-IVb non-metastatic HNC according to the seventh&#xD;
             edition of the American Joint Committee on Cancer Staging System (AJCC 2010)&#xD;
&#xD;
          -  receipt of definitive CCRT&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0-1&#xD;
&#xD;
          -  creatinine clearance ≥ 60 mL/min/1.73 m2 calculated by the Cockcroft-Gault formula&#xD;
&#xD;
          -  absence of mucositis&#xD;
&#xD;
          -  able to tolerate oral feeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  receipt of curative surgery for HNC&#xD;
&#xD;
          -  allergies to any component of the immunonutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Arunee Dechaphunkul</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>immunonutrition</keyword>
  <keyword>concurrent chemoradiation</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

